- Home
- ECOR vs LPCN Comparison
ECOR vs LPCN Comparison
Compare ECOR & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECOR | LPCN |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 61.8M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ECOR | LPCN |
|---|---|---|
| Price | $7.34 | $9.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $22.00 | $15.00 |
| AVG Volume (30 Days) | 97.1K | ★ 205.3K |
| Earning Date | 03-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,835,000.00 | $4,322,693.00 |
| Revenue This Year | $28.92 | N/A |
| Revenue Next Year | $40.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.90 | N/A |
| 52 Week Low | $4.16 | $2.52 |
| 52 Week High | $19.49 | $12.37 |
Technical Indicators
Market Signals| Indicator | ECOR | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 61.22 | 58.23 |
| Support Level | $6.40 | $9.30 |
| Resistance Level | $8.30 | $11.11 |
| Average True Range (ATR) | 0.86 | 1.20 |
| MACD | 0.14 | -0.16 |
| Stochastic Oscillator | 71.53 | 44.18 |
Price Performance
Historical ComparisonAbout ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.